Prognostic value of Urinary TGF-β1 in Hemolytic Uremic Syndrome: a pilot study.
Transforming growth factor β1 (TGF-β1) is the main profibrotic cytokine. Its urinary excretion reflects intra-renal production; thus, we conjectured that it is elevated during hemolytic uremic syndrome related to Shiga-toxin-producing Escherichia coli (STEC-HUS). In this pilot study we explored the ability of baseline TGF-β1 excretion (exposure variable) to predict renal prognosis at six months (outcome variable). Secondarily, we compared changes of cytokine levels through the study period between patients with opposite evolution. Urinary TGF-β1 concentrations were measured prospectively in 24 children with STEC-HUS on admission, 15, 30, 60, 90 and 180 days. Normal values were obtained from 20 healthy subjects. Baseline TGF-β1 concentrations predicted renal outcomes with an AUC of 1 (95%CI 0.85-1; sensitivity 100%, specificity 100%) with best cutoff level >293.7 pg/mg uCr. None patient with low TGF-β1 levels, unlike all with high concentrations, developed persistent renal impairment (20/0 vs. 4/4 respectively, P=0.0001). The latter had higher cytokine levels (P<0.05) at each time point without reaching normal concentrations (<45 pg/mg uCr). Baseline urinary TGF-β1 levels accurately predicted short-term renal outcomes in STEC-HUS children and cytokine excretion during the first six months after diagnosis was higher among those with worse evolution. Larger studies are needed to validate these findings.